SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw unusually large options trading activity on Friday. Traders acquired 12,381 call options on the stock. This represents an increase of ...

Barclays analyst Peter Lawson maintained a Buy rating on MacroGenics (MGNX – Research Report) today and set a price target of $8.00. The ...

Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of SWTX's ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See why SWTX is a good speculative “Buy”.

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline ...

The FDA has approved SpringWorks Therapeutics’s mirdametinib (Gomekli) for adult and paediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic ...

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines.

Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for SpringWorks Therapeutics SWTX revealed 9 unusual trades. Delving into the ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following cancellations from other public events since the ...